The Influence of Atorvastatin Treatment on Homocysteine Metabolism and Oxidative Stress in an Experimental Model of Diabetic Rats

• Published in: Life (Basel, Switzerland) Switzerland), 2024-11, Vol.14 (11), p.1414
• Main Authors: Clim, Andreea, Maranduca, Minela Aida, Filip, Nina, Tănase, Daniela Maria, Floria, Mariana, Pinzariu, Alin Constantin, Popa, Irene Paula, Nemteanu, Roxana, Cozma, Tudor Cristian, Faur, Flaviu Ionut, Serban, Dragomir Nicolae, Scripcariu, Dragoș Viorel, Serban, Ionela Lacramioara
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Antioxidants; Atherosclerosis; Atorvastatin; Biomarkers; Body weight; Cardiovascular disease; Cholesterol; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Endothelium; experimental models of diabetes mellitus; Folic acid; Glutathione; Glutathione peroxidase; High fat diet; Homeostasis; Homocysteine; Inflammation; Insulin resistance; Kinases; lipid profile; Lipids; Metabolic disorders; Mortality; Nitric oxide; Obesity; Oxidation; Oxidative metabolism; Oxidative stress; Peroxidase; Physiological aspects; Plasma; Risk factors; Statins; Streptozocin; Superoxide; Superoxide dismutase; Type 2 diabetes; Vitamin B12
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life14111414

In our experimental study, we evaluated the influence of treatment with atorvastatin on the antioxidant activity of intracellular and extracellular systems factors, homocysteine levels (Hcy), and lipid profiles in obese and diabetic rats. Twenty-one male Wistar rats, aged 6 months, 450-550 g, were allocated into three groups. From the beginning of the study, the first group (G-I, control) received only standard food, while the second and third groups (G II-obese, G III-diabetic) were administered a high-fat diet (HFD) with 2% cholesterol. After 2 weeks of accommodation, the specimens in G-III were injected intraperitoneal (i.p.) streptozotocin (35 mg of body weight, pH 4.5), intervention followed by the onset of type 2 diabetes mellitus. Following confirmation of diabetes onset, the specimens in G III were administered concomitantly with the HFD a daily gavage of atorvastatin 20 mg of body weight/day for 20 days. We measured, at the beginning and the end of the study, the Hcy levels, lipid profile, vitamin B12, B6, folic acid, and various parameters of oxidative stress (OS)-total antioxidant status (TAS), glutathione peroxidase (GPX) and superoxide dismutase (SOD). After treatment with atorvastatin, the lipid profile in G III significantly improved compared to the other two groups, but enzymatic markers of oxidative stress did not closely parallel this trend. However, after the treatment of statin, we observed an important reduction in Hcy values. Our results demonstrate that treatment with atorvastatin can be used not only for its lipid-lowering properties and antioxidant effects but also to reduce Hcy concentration in this experimental model of diabetic rats. Moreover, atorvastatin therapy improves lipid profiles, reduces inflammation, suppresses oxidation, and decreases Hcy levels, potentially preventing major adverse cardiovascular events.